Publications by authors named "Y Kamihara"
Though multiple relapses and serial shortening of remission is one of the characteristics of follicular lymphoma (FL), standard third- and later-line treatments with clear evidence have not yet been established. Tazemetostat, the first oral enhancer of zester homolog 2 ( inhibitor, showed a favorable clinical outcome and safety profile against relapsed mutant FL in a clinical trial and was applied to this clinical setting. Peripheral blood involvement, known as the leukemic phase, was observed in approximately 10% of patients with FL and reported as a poor prognostic factor.
View Article and Find Full Text PDFArticle Synopsis
- Hypertrophic pachymeningitis (HP) is a rare condition that causes inflammation and thickening of the dura mater, the outer layer of the protective covering of the brain and spinal cord.
- It is commonly associated with other inflammatory diseases, particularly ANCA-associated vasculitis and IgG4 related disease, with very few cases linked to hematologic disorders.
- The reported case discusses a patient with myelodysplastic syndrome (MDS) who developed HP, suggesting a possible connection between these two conditions.
To assess the association between gestational weight gain (GWG) and the risk of developing chronic diseases in later life, this historical cohort study of 318 non-overweight women was conducted between April 2017 and November 2020 at a hospital in Tokyo. Data about GWG in the last pregnancy and the development of any chronic diseases of the subjects were retrieved from the women's Maternal and Child Health Handbooks and through a questionnaire survey, respectively. The outcomes were chronic diseases, such as diabetes mellitus (DM), hypertension, hyperlipidemia, and being overweight (body mass index [BMI] ≥ 25 kg/m).
View Article and Find Full Text PDFArticle Synopsis
- Overexpression of inhibitor of apoptosis (IAP) proteins is linked to poor outcomes in multiple myeloma (MM), prompting research into IAP inhibitors (IAPi) for treatment.
- While existing inhibitors like LCL161 are not fully effective, a new compound, AZD5582, shows strong binding to XIAP, leading to better anti-cancer activity in MM cell lines by inducing apoptosis and inhibiting growth.
- AZD5582 also demonstrates enhanced effectiveness when combined with existing therapies, suggesting its potential as a promising monotherapy and in combination strategies for treating MM.